Publications by authors named "S B Cogliatti"
In myelofibrosis, comorbidities (CMs) add prognostic information independently from the Dynamic International Prognostic Scoring System (DIPSS). The Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) offers a simple tool for CM assessment as it is calculable after having performed a careful history and physical examination, a small routine chemistry panel (including creatinine and liver enzymes) and a limited set of functional diagnostics. To assess the prognostic impact of the MDS-CI in addition to the DIPSS and the Mutation-Enhanced International Prognostic Scoring System (MIPSS)-70, we performed a retrospective chart review of 70 MF patients who had not received allogeneic stem cell transplantation (primary MF, n = 51; secondary MF, n = 19; median follow-up, 40 months) diagnosed at our institution between 2000 and 2020.
View Article and Find Full Text PDFIn myelofibrosis, the C-reactive protein (CRP)/albumin ratio (CAR) and the Glasgow Prognostic Score (GPS) add prognostic information independently of the Dynamic International Prognostic Scoring System (DIPSS). Their prognostic impact, if molecular aberrations are considered, is currently unknown. We performed a retrospective chart review of 108 MF patients (prefibrotic MF n = 30; primary MF n = 56; secondary MF n = 22; median follow-up 42 months).
View Article and Find Full Text PDFArticle Synopsis
- - Splenic marginal zone B-cell lymphoma (SMZL) is a complex condition with varying clinical outcomes, influenced by multiple gene mutations and diverse regulatory pathways, making it critical to identify different subgroups based on their genetic and environmental features.
- - Researchers analyzed 303 spleen samples from an international study to understand these subgroups, ultimately identifying two main genetic clusters: NNK (58% of cases) and DMT (32% of cases), each with unique genetic profiles and survival outcomes.
- - The study revealed two types of immune microenvironments within SMZL: immune-suppressive and immune-silent, highlighting their distinct clinical implications and the potential for improving classification and targeted therapies in this disease.
This translational study aimed at gaining insight into the effects of lenalidomide in acute myeloid leukemia (AML). Forty-one AML patients aged 66 or older of the Swiss cohort of the HOVON-103 AML/SAKK30/10 study were included. After randomization, they received standard induction chemotherapy with or without lenalidomide.
View Article and Find Full Text PDF